Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Expected to Post Earnings of -$0.67 Per Share

Equities research analysts forecast that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will post ($0.67) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Protagonist Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.77). Protagonist Therapeutics posted earnings per share of ($0.21) in the same quarter last year, which would suggest a negative year over year growth rate of 219%. The company is expected to announce its next quarterly earnings report on Wednesday, November 3rd.

According to Zacks, analysts expect that Protagonist Therapeutics will report full-year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($2.82) to ($2.36). For the next year, analysts anticipate that the firm will report earnings of ($2.35) per share, with EPS estimates ranging from ($3.52) to ($1.33). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.14). Protagonist Therapeutics had a negative net margin of 299.39% and a negative return on equity of 30.58%. The business had revenue of $2.27 million during the quarter, compared to analyst estimates of $5.60 million.

PTGX has been the subject of a number of research analyst reports. Piper Sandler upped their price target on shares of Protagonist Therapeutics from $53.00 to $93.00 and gave the company an “overweight” rating in a report on Friday, July 30th. Zacks Investment Research downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. HC Wainwright restated a “buy” rating and set a $50.00 price objective (down previously from $60.00) on shares of Protagonist Therapeutics in a report on Monday. JMP Securities cut their price objective on Protagonist Therapeutics from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday. Finally, SVB Leerink boosted their price objective on Protagonist Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $51.63.

Shares of NASDAQ PTGX opened at $15.47 on Monday. Protagonist Therapeutics has a twelve month low of $12.80 and a twelve month high of $50.54. The company has a market capitalization of $735.61 million, a price-to-earnings ratio of -8.06 and a beta of 1.56. The firm has a 50-day moving average of $45.11 and a two-hundred day moving average of $37.62.

In other news, insider David Y. Liu sold 14,779 shares of the company’s stock in a transaction dated Tuesday, August 17th. The stock was sold at an average price of $47.56, for a total value of $702,889.24. The sale was disclosed in a filing with the SEC, which is accessible through this link. 5.00% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC grew its stake in shares of Protagonist Therapeutics by 8.3% in the 2nd quarter. FMR LLC now owns 7,116,383 shares of the company’s stock valued at $319,383,000 after buying an additional 545,156 shares in the last quarter. BlackRock Inc. boosted its position in Protagonist Therapeutics by 1.3% during the second quarter. BlackRock Inc. now owns 3,040,541 shares of the company’s stock worth $136,459,000 after purchasing an additional 38,912 shares during the period. Vanguard Group Inc. boosted its position in Protagonist Therapeutics by 6.9% during the second quarter. Vanguard Group Inc. now owns 2,288,034 shares of the company’s stock worth $102,686,000 after purchasing an additional 147,487 shares during the period. Point72 Asset Management L.P. boosted its position in Protagonist Therapeutics by 22.6% during the second quarter. Point72 Asset Management L.P. now owns 1,155,200 shares of the company’s stock worth $51,845,000 after purchasing an additional 212,900 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Protagonist Therapeutics by 8.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 986,254 shares of the company’s stock worth $44,263,000 after purchasing an additional 72,664 shares during the period.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Read More: Guidelines for Successful Channel Trading

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.